Shenzhen Ruihua Pharmaceutical Technology

Shenzhen Ruihua Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Shenzhen, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on precision oncology and metabolic diseases, utilizing a structure-based drug design approach to develop highly selective and potent inhibitors. Its lead candidate, RH001, is a pan-FGFR inhibitor currently in Phase 2 clinical trials for the treatment of cholangiocarcinoma and urothelial carcinoma. Ruihua's pipeline also includes promising candidates targeting RET for lung cancer and URAT1 for gout, reflecting its commitment to addressing significant unmet medical needs through internal R&D excellence.